摘要
目的大株红景天注射液联合XELOX方案化疗对老年晚期直肠癌(CC)患者肿瘤标志物及心肌损伤标志物的影响。方法选择2020年2月—2022年3月本院收治的83例老年晚期CC患者作为研究对象,随机数表法分观察组(42例)和对照组(41例)两组。两组均给予放疗,在此基础上对照组予以XELOX方案化疗,观察组予以大株红景天注射液联合XELOX方案化疗,对比两组疗效、血清肿瘤标志物[肌酸激酶同工酶-MB(CK-MB)、糖类抗原-125(CA-125)]水平、心肌损伤标志物[肌酸激酶(CK)、心肌肌钙蛋白Ⅰ(cTnI)、癌胚抗原(CEA)]水平及不良反应。结果观察组疾病控制率为95.24%,与对照组的95.12%相比,差异无统计学意义(P>0.05);治疗前两组血清CEA、CA-125水平对比,差异无统计学意义(P>0.05),治疗后血清CEA、CA-125水平降低,但组间对比,差异无统计学意义(P>0.05);治疗后两组血清CK、CK-MB、cTnI水平升高,且观察组CK、CK-MB、cTnI水平分别为(113.59±11.33)U/L、(17.35±5.29)U/L及(68.36±6.82)ng/L,均低于对照组的(148.73±10.86)U/L、(20.37±5.71)U/L及(76.73±6.47)ng/L(P<0.05)。观察组中性粒细胞减少6例,腹泻3例,白细胞减少5例,恶心呕吐4例;对照组中性粒细胞减少8例,腹泻1例,白细胞减少5例,恶心呕吐5例。观察组不良反应发生率为42.86%(18/42),与对照组的46.34%(19/41)相比,差异无统计学意义(χ^(2)=0.102,P=0.750)。结论大株红景天注射液联合XELOX方案化疗治疗老年晚期CC能有效减轻患者心肌损害且不影响化疗效果,安全性高,有助于增加患者化疗耐受性。
Objective To investigate the effect of dazhu Rhodiola injection combined with XELOX regimen on tumor markers and myocardial injury markers in elderly patients with advanced rectal cancer(CC).Methods A total of 83 patients elderly with advanced CC,those were admitted to central hospital of Xinxiang from February 2020 to March 2022,were enrolled as study subjects.According to random number table method,they were divided into observation group(42 cases)and control group(41 cases).Patients in both groups were given radiotherapy.On this basis,the control group was given XELOX chemotherapy regimen,and the observation group was given dazhu Rhodiola injection combined with XELOX regimen chemotherapy.The therapeutic effect,incidence of adverse reactions,serum levels of tumor markers(Creatine Kinase Isoenzyme-MB,CK-MB;carbohydrate antigen-125,CA-125),and myocardial injury markers(creatine kinase,CK;cardiac troponin I,cTnI;carcino-embryonic antigen,CEA)were compared.Results There was no significant difference in the disease control rate between the control group and the observation group(95.24%vs 95.12%,P>0.05).There was no significant difference in serum CEA and CA-125 levels before treatment between the two groups(P>0.05),and the serum CEA and CA-125 levels decreased after treatment,but there was no significant difference between the two groups(P>0.05).After treatment,the serum levels of CK,CK-MB and cTnI in the two groups increased,and the levels of CK,CK-MB and cTnI in the observation group were(113.59±11.33)U/L,(17.35±5.29)U/L and(68.36±6.82)ng/L,respectively.And the levels were lower than(148.73±10.86)U/L,(20.37±5.71)U/L and(76.73±6.47)ng/L in the control group,and the differences were statistically significant(P<0.05).In the observation group,there were 6 cases of neutropenia,3 cases of diarrhea,5 cases of leukopenia and 4 cases of nausea and vomiting.In the control group,there were 8 cases of neutropenia,1 case of diarrhea,5 cases of leukopenia and 5 cases of nausea and vomiting.The incidence of adverse reactions in the observation group was 42.86%(18/42),and it was 46.34%(19/41)in the control group,however,the difference was not statistically significant(χ^(2)=0.102,P=0.750).Conclusions Dazhu Rhodiola injection combined with XELOX regimen in the treatment of elderly patients with advanced CC could effectively reduce myocardial damage without affecting the efficacy of chemotherapy,with high safety,and it is contribute to increase the tolerance of chemotherapy in patients.
作者
宋亚熙
李春青
田国防
Song Yaxi;Li Chunqing;Tian Guofang(The first ward,medical oncology,Xinxiang central hospital/fourth clinical school of Xinxiang Medical College,Xinxiang,Henan,453000,China)
出处
《齐齐哈尔医学院学报》
2023年第10期950-953,共4页
Journal of Qiqihar Medical University
关键词
大株红景天注射液
XELOX方案
老年
晚期
直肠癌
癌胚抗原
Dazhu Rhodiola injection
XELOX plan
The old age
Advanced stage
Rectal cancer
Carcinoembryonic antigen
